⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025

Table 3 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Robert Wesolowski Hope S. Rugo Jennifer M. Specht Hyo S. Han Peter Kabos Ulka N. Vaishampayan Seth A. Wander Keerthi Gogineni Alexander I. Spira Anne F. Schott Maysa Abu‐Khalaf Sarah C. Mutka Samuel Suzuki Brian Sullivan Igor Gorbatchevsky Rachel M. Layman

View Full Paper

Ask AI

Bookmark

Share

Key Points

Over 20% of patients experienced treatment-emergent adverse events during the trial.
The safety analysis involved 41 patients receiving the combination therapy with hormone receptor-positive, HER2-negative advanced breast cancer.
Combination therapy with gedatolisib, palbociclib, and letrozole may offer a novel treatment strategy.
Findings may support changes in therapy approaches for patients with advanced breast cancer.

Implication

Assessment of safety and common adverse events in patients with hormone receptor-positive, HER2-negative advanced breast cancer following treatment.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wesolowski et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a219a5 https://doi.org/10.1158/1078-0432.30255517

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 4 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025
2Table 1 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025
3Table 2 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025
4Figure 2 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025
5Figure 1 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer2025